29/06/2009 (Agence Europe) - On Thursday 25 June, the European Medicines Agency recommended that patients in greatest need of treatment be given priority access to Cerezyme and Fabrazyme, which are produced by the US laboratory Genzyme. This is to ensure continued treatment for those suffering from Gaucher disease and Fabry disease. The recommendation comes after production was shut down after a viral contamination was found, requiring the Allston Landing site in the United States to be...